We are international
Donate
TEXT SIZE   


ASH 2011: Dr. Richardson - Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results
Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
12.07.11


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles